Human Study Indicates Crocin Benefits Multiple Sclerosis Patients
Reading time: 1 minutes
Level of expertise: Low
Multiple sclerosis (MS) is an autoimmune disease that potentially disables the central nervous system of the brain and spinal cord. As one of the most common multifactorial disorders, MS is similar to Alzheimer’s disease. Although the exact cause of MS is unknown, it is believed that protection against oxidative and inflammation damage plays a significant role in stopping the process of the disease. Crocin, a main active constituent of saffron, potent antioxidant and anti-inflammation agent with multi-target health effects, has gained significant attention recently.
A 4-week double‐blind, randomized, and placebo‐controlled trial of crocin in multiple sclerosis patients was recently published in Journal Biochemical and Molecular Toxicology (2019;e22410).
Highlights of the study:
- Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor‐alpha (TNF‐α), and interleukin 17 (IL-17) as well as a significant increase in the total antioxidant capacity in the serum of patients treated with crocin (30mg/day) compared with the placebo group.
- Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.
- The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.